XML 21 R11.htm IDEA: XBRL DOCUMENT v3.25.2
Stock-Based Compensation
 3 Months Ended
Jun. 30, 2025
Stock-Based Compensation [Abstract]  
STOCK-BASED COMPENSATION

NOTE 5 – STOCK-BASED COMPENSATION

 

Amended and Restated 2017 Equity Incentive Plan

 

In October 2017, the Company’s board of directors (the “Board”) approved the 2017 Equity Incentive Plan (the “Plan”) with 1,000,000 shares of common stock reserved for issuance. In January 2020 and August 2021, the Board approved increases in the number of shares reserved for issuance under the Plan by 333,334 and 1,333,334 shares, respectively. In January 2023, February 2024 and February 2025, the Company’s stockholders approved increases in the number of shares reserved for issuance under the Plan by an additional 2,000,000, 3,000,000 and 3,000,000 shares, respectively. Under the Plan, eligible employees, directors and consultants may be granted a broad range of awards, including stock options, stock appreciation rights, restricted stock, performance-based awards and restricted stock units (“RSUs”). The Plan is administered by the Board or, in the alternative, a committee designated by the Board. 

 

Stock-Based Compensation Expense

 

Stock options granted by the Company generally vest over 36 months and have a 10-year term. As of June 30, 2025, the unamortized compensation cost related to stock options was approximately $2,369,550 and is expected to be recognized as expense over a weighted-average period of approximately 1.21 years.

 

In April 2025, under its Two-Part FDA Submission and Product Milestone Bonus Program, the Company granted stock options for 1,941,000 shares, which are subject to vesting based upon achievement of certain performance milestones by the Company and continued service by the optionee. As of June 30, 2025, the Company had commenced expense recognition for all 1,941,000 of these option shares based on its assessment of the probability of achievement of the applicable performance requirements, including (i) submission of the 510(k) to the FDA for the Pivot pump product on or before October 31, 2025 and (ii) validation of the manufacturing line validated for the Pivot pump product with capacity to serve 6,000 patents by March 15, 2026.

 

The weighted-average grant date fair value of options granted was $0.75 and $1.33 per share for the three months ended June 30, 2025 and 2024, respectively. The following assumptions were used in the fair-value method calculations:

 

   Three Months Ended
June 30,
   2025  2024
Risk-free interest rates  3.79% - 4.14%  4.33% - 4.43%
Volatility  105% - 107%  118% - 123%
Expected life (years)  5.0 - 5.7  5.0 - 5.7

 

The fair values of options at the grant date were estimated utilizing the Black-Scholes valuation model, which includes simplified methods to establish the fair term of options, as well as average volatility. The risk-free interest rate was derived from the Daily Treasury Yield Curve Rates, as published by the U.S. Department of the Treasury as of the grant date for terms equal to the expected terms of the options. A dividend yield of zero was applied because the Company has never paid dividends and has no intention to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur.

 

The following table summarizes the activity in the shares available for grant under the Plan during the three months ended June 30, 2025:

 

       Options Outstanding 
           Weighted 
   Shares       Average 
   Available   Number of   Exercise 
   for Grant   Shares   Prices 
Balance at March 31, 2025   5,397,872    4,917,090   $3.17 
Share awards   (6,375)   
—
    0.68 
Options granted   (2,291,172)   2,291,172    0.93 
Options cancelled and returned to the Plan   8,056    (8,056)   1.52 
Balance at June 30, 2025   3,108,381    7,200,206   $2.46 

There were no stock options exercised during the three months ended June 30, 2025. A stock option was exercised on a cashless basis for 7,530 shares of common stock during the three months ended June 30, 2024. During the three months ended June 30, 2025 and 2024, the Company awarded 6,375 and 3,875 shares, respectively, to its non-employee directors under the Company’s outside director compensation plan. For the three months ended June 30, 2025 and 2024, the Company recorded stock-based compensation expense for these share awards of approximately $4,000 and $6,000, respectively.

 

A summary of restricted stock unit (RSU) activity under the Plan is presented below.

 

       Weighted
Average		 
   Number of
Shares		   Grant-Date
Fair Value		 
Balance at March 31, 2025   104,168   $0.91 
Vested   (20,833)  0.91 
Non-vested shares at June 30, 2025   83,335   $0.91 

 

The total intrinsic value of RSUs outstanding as of June 30, 2025 was approximately $63,000. The unamortized compensation cost at June 30, 2025 was approximately $77,000 related to RSUs and is expected to be recognized as expense over a period of approximately one year.

 

The following table summarizes the range of outstanding and exercisable options as of June 30, 2025:

 

   Options Outstanding   Options Exercisable 
Range of Exercise Price  Number
Outstanding		   Weighted
Average
Remaining
Contractual
Life
(in Years)		   Weighted
Average
Exercise
Price		   Number
Exercisable		   Weighted
Average
Exercise
Price		   Aggregate
Intrinsic
value		 
$0.68 - $2.28   5,767,932    8.66   $1.30    2,533,951   $1.54   $2,812 
$3.95 - $7.51   933,145    5.94   $5.30    927,728   $5.31    
—
 
$8.61 - $17.70   499,129    5.98   $10.56    499,129   $10.56    
—
 
$0.68 - $17.70   7,200,206    8.12   $2.46    3,960,808   $3.56   $2,812 

 

The common stock on the Company’s principal trading market over the exercise price of the option.